IGF2BP1 / Insulin-like growth factor 2 mRNA-binding protein 1 · IHC design guide

Design Immunohistochemistry for IGF2BP1

Plan IGF2BP1 IHC-P with testis preleptotene spermatocytes as a strong positive reference (HPA tissue IHC). The guide pairs the catalog antibody’s 1:25 dilution with adipocytes as a negative reference and assessment of cytoplasmic staining (datasheet A02007-1; HPA tissue IHC).

Evidence assembled Oct 2026 · For research use; verify linked source records and product datasheet before use

Immunohistochemistry protocol sheet for IGF2BP1 (IHC for IGF2BP1): expected localisation Cytoplasmic staining in testis and ovary (HPA tissue IHC), antibody A02007-1, validated IHC image, and IHC protocol steps — Printable **IGF2BP1** IHC protocol sheet — expected localisation Cytoplasmic staining in testis and ovary (HPA tissue IHC), antibody A02007-1, controls and protocol steps. Open the full IGF2BP1 IHC guide →

Navigate to: Protocols Staining pattern Controls Antibodies

IGF2BP1 Immunohistochemistry Experimental Design Guide

Expected localisation, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.

Must know before staining

	Expected localisation	Cytoplasmic staining in testis and ovary (HPA tissue IHC)
	Staining pattern	Cytoplasmic in seminiferous duct and ovarian follicle cells (HPA tissue IHC)
	Antigen retrieval	Citrate pH 6 HIER, heat-mediated (datasheet A02007-1)
	Positive control ⓘ	Testis+2 more · see all
	Negative control ⓘ	Adipose tissue+4 more · see all

Important caveats

Reasons your staining may differ from the expected pattern.

	Fixation	Formaldehyde-fixed paraffin sections (selected-SKU IHC image A02007-1)
	Caveat	Staining and RNA show only medium consistency (HPA tissue IHC)
	Regulation	Embryonic and cancer expression (UniProt)
	Isoform / epitope	Two isoforms; C-terminal epitope coverage is unspecified (UniProt; datasheet A02007-1)

Section 1

Recommended IGF2BP1 IHC & IF Protocols

The catalog antibody’s IHC-P protocol (datasheet A02007-1) is accompanied by published methods for lung adenocarcinoma (PMC12967950) and osteosarcoma (PMC6449306).

Recommended immunohistochemistry (IHC-P) protocol parameters
Sample	Formaldehyde-fixed, paraffin-embedded human testis tissue (datasheet A02007-1)
Fixation	Image formalin-fixed; duration unreported (datasheet A02007-1); verify before use.
Sectioning	4–5 µm sections on charged slides (standard)
Deparaffinisation	Xylene, graded ethanol series to water (standard)
Antigen retrieval	Heat retrieval: Citrate pH 6 (datasheet A02007-1); 20 min, 95–100 °C (standard)
Peroxidase block	3% H2O2, 10 min, room temperature (standard)
Blocking	10% normal serum of the secondary host, 30 min, room temperature (standard)
Primary antibody	Rabbit anti-IGF2BP1, 1:25 (datasheet A02007-1)
Primary incubation	1 hours at 37°C (datasheet A02007-1)
Detection	HRP-polymer secondary, DAB chromogen 5–10 min (standard)
Counterstain	Hematoxylin, blue, dehydrate and mount (standard)
Expected result	IGF2BP1-positive staining in preleptotene spermatocytes of testis (HPA tissue IHC: High). HPA tissue profile: Cytoplasmic expression mainly in cells in seminiferous ducts of testis and follicle cells in ovary. No signal in the no-primary control.

💡Decision noteStart with heat-mediated citrate pH 6 retrieval for the catalog antibody (datasheet A02007-1); the lung adenocarcinoma article does not specify retrieval conditions (PMC12967950).

Section 2

What Is the Expected IGF2BP1 Staining Pattern?

IGF2BP1 should appear mainly in the cytoplasm of preleptotene spermatocytes in testis, with weaker staining in ovarian follicle cells and kidney collecting ducts (HPA tissue IHC: High; Medium; Medium). It has no transmembrane segment and can occupy cytoplasmic granules and perinuclear regions (UniProt Q9NZI8). HPA rates its tissue IHC reliability Enhanced, with medium consistency between staining and RNA expression (HPA tissue IHC).

What am I looking at on my slide?
Strong cytoplasmic staining in testicular preleptotene spermatocytes, with less intense staining in ovarian follicle cells or kidney collecting ducts (HPA tissue IHC).	This matches the reported High testis and Medium ovary and kidney patterns (HPA tissue IHC). Score the identified cells and their cytoplasm; avoid treating every cell in a positive tissue as equally positive (standard IHC interpretation).
Predominantly nuclear staining, or a membrane outline with little cytoplasmic signal (HPA tissue IHC; UniProt Q9NZI8).	Review this as a possible artefact because the tissue pattern is cytoplasmic and IGF2BP1 has no transmembrane segment (HPA tissue IHC; UniProt Q9NZI8). Discrete nuclear foci are reported, so limited nuclear signal alone does not establish failure (UniProt Q9NZI8).
Strong staining in cells reported as undetected, such as adipocytes in adipose tissue, while expected positive cells lack signal (HPA tissue IHC).	Consider cross-reactivity or endogenous detection activity, then compare with appropriate controls (standard IHC practice). HPA's undetected category describes its observations; it does not prove that every specimen of that cell type must be blank (HPA tissue IHC).
Color covers stroma, empty spaces, and many cell types without a discernible cytoplasmic pattern (standard IHC interpretation).	Treat this as background until controls support a cellular signal (standard IHC practice). Excess primary antibody, incomplete blocking, or residual detection reagent can obscure the compartment and cell-type pattern reported by HPA (standard IHC practice; HPA tissue IHC).
No staining in testicular preleptotene spermatocytes on an otherwise readable section (HPA tissue IHC: High).	The expected positive reference has failed; do not call other negative areas biologically negative from this run (standard IHC interpretation). Check section quality and the primary, retrieval, and detection steps with controls before interpreting absence (standard IHC practice).

💡Expected IGF2BP1 appearanceCall a slide positive when identified preleptotene spermatocytes show clear, relatively strong cytoplasmic staining; ovarian follicle cells and kidney collecting ducts may show medium staining, whereas broad extracellular color or dominant membrane outlines are suspect (HPA tissue IHC; UniProt Q9NZI8; standard IHC interpretation).

How each factor affects the staining
Cell type and tissue context (HPA tissue IHC)	HPA reports High staining in testicular preleptotene spermatocytes, Medium in ovarian follicle cells and kidney collecting ducts, and Low in bronchial respiratory epithelium (HPA tissue IHC). Select and score the actual cell population, since a tissue-wide average can hide its pattern (standard IHC interpretation).
Compartment and physiological state (UniProt Q9NZI8; HPA tissue IHC)	Cytoplasmic staining is the tissue reference pattern (HPA tissue IHC). UniProt also lists perinuclear regions, mRNP granules, stress granules under cellular stress, and discrete nuclear foci; these locations are contextual possibilities, not a requirement for every paraffin section (UniProt Q9NZI8).
Antibody evidence (HPA antibodies; HPA tissue IHC)	HPA021367 and HPA062273 each have Enhanced IHC validation (HPA antibodies). The overall tissue profile has medium staining-to-RNA consistency, so use the reported cell pattern and controls when assessing a discordant specimen (HPA tissue IHC; standard IHC practice).
IF/ICC Q&A: Where should fluorescence appear? (HPA subcellular ICC-IF)	Mainly in the cytosol; HPA supports that location and provides ICC-IF images from CACO-2, Hep-G2, and U2OS (HPA subcellular ICC-IF). This subcellular evidence helps interpret fluorescence but does not prescribe an IF/ICC procedure (HPA subcellular ICC-IF).

Why is my staining missing, weak or wrong?
Situation	Likely cause	Next action
Testis positive control is blank in the expected cells (HPA tissue IHC: preleptotene spermatocytes, High).	A failed staining run, unsuitable section, or missed primary or detection step can suppress visible signal (standard IHC practice).	Confirm that the target cells are present, then review reagent delivery, antigen retrieval, and detection using run controls; repeat before scoring negatives (standard IHC practice).
Expected cells stain weakly in testis while controls show that detection worked (HPA tissue IHC: High).	The assay conditions or specimen may yield less visible signal than HPA's reference pattern (standard IHC interpretation; HPA tissue IHC).	Target-specific fixation effects are not established by the supplied assay evidence. Verify with a matched IHC source before attributing a result to fixation.
Brown signal fills the section and hides cytoplasmic borders (standard IHC interpretation).	Excess reagent signal, insufficient washing or blocking, or endogenous detection activity can produce diffuse background (standard IHC practice).	Inspect no-primary and detection controls; adjust blocking, washing, or reagent concentration according to the detection system (standard IHC practice). Reassess the HPA cell-specific pattern only after background is controlled (HPA tissue IHC).
A crisp membrane rim dominates the stain (HPA tissue IHC: cytoplasmic pattern).	That distribution conflicts with the reported tissue pattern and the absence of a transmembrane segment; nonspecific labeling is possible (HPA tissue IHC; UniProt Q9NZI8).	Check cell morphology and controls, and compare a validated positive tissue with the same run before assigning the rim to IGF2BP1 (standard IHC practice; HPA tissue IHC).
Adipocytes stain strongly although expected testis cells also stain (HPA tissue IHC).	HPA reports adipocytes in adipose tissue as Not detected; cross-reactivity or endogenous activity is possible, but a single discordant specimen is inconclusive (HPA tissue IHC; standard IHC interpretation).	Compare no-primary and detection controls, review cell identification, and seek a second validated antibody if the unexpected pattern persists (standard IHC practice; HPA antibodies).
Only puncta or nuclear foci are visible, with little general cytoplasmic staining (HPA tissue IHC; UniProt Q9NZI8).	IGF2BP1 can occur in mRNP granules and discrete nuclear foci; stress granule recruitment depends on cellular stress (UniProt Q9NZI8). The distribution alone cannot establish specificity (standard IHC interpretation).	Confirm a matching positive cell population and assess controls before scoring the puncta; report the compartment actually seen without assuming stress or an IF/ICC pattern in the tissue section (HPA tissue IHC; standard IHC interpretation).

Source: UniProt Q9NZI8 Human Protein Atlas tissue Human Protein Atlas subcellular

Experiment evidence

IHC & IF images showing IGF2BP1 staining

A02007-1 staining IGF2BP1 in human testis tissue sections by Immunohistochemistry (IHC-P -paraformaldehyde-fixed, paraffin-embedded sections). Tissue was fixed with formaldehyde and blocked with 3% BSA for 0. 5 hour at room temperature; antigen retrieval was by heat mediation with a citrate buffer (pH6). Samples were incubated with primary antibody (1/25) for 1 hours at 37°C. A undiluted biotinylated goat polyvalent antibody was used as the secondary antibody.

A02007-1 · IHCA02007-1 staining IGF2BP1 in human testis tissue sections by Immunohistochemistry (IHC-P -paraformaldehyde-fixed, paraffin-embedded sections

A02007-1 staining IGF2BP1 in human lung adenocarcinoma sections by Immunohistochemistry (IHC-P -paraformaldehyde-fixed, paraffin-embedded sections). Tissue was fixed with formaldehyde and blocked with 3% BSA for 0. 5 hour at room temperature; antigen retrieval was by heat mediation with a citrate buffer (pH6). Samples were incubated with primary antibody (1/25) for 1 hours at 37°C. A undiluted biotinylated goat polyvalent antibody was used as the secondary antibody.

A02007-1 · IHCA02007-1 staining IGF2BP1 in human lung adenocarcinoma sections by Immunohistochemistry (IHC-P -paraformaldehyde-fixed, paraffin-embedded se

HPA · Cerebral cortexHuman Protein Atlas IHC, Cerebral cortex. Source: https://www.proteinatlas.org/ENSG00000159217-IGF2BP1/tissue/cerebral+cortex#imid_18540099

HPA · ColonHuman Protein Atlas IHC, Colon. Source: https://www.proteinatlas.org/ENSG00000159217-IGF2BP1/tissue/colon#imid_18540017

HPA · LiverHuman Protein Atlas IHC, Liver. Source: https://www.proteinatlas.org/ENSG00000159217-IGF2BP1/tissue/liver#imid_18540026

HPA · KidneyHuman Protein Atlas IHC, Kidney. Source: https://www.proteinatlas.org/ENSG00000159217-IGF2BP1/tissue/kidney#imid_18540019

HPA · ICC-IF CACO-2Human Protein Atlas immunofluorescence, CACO-2, antibody HPA021367; green = IGF2BP1, blue = nucleus, red = microtubules.

← swipe / scroll for more images →

Real IHC / IF data behind the staining-pattern expectations in this section.

Sample controls for IGF2BP1 IHC & IF

🧪Run testis first: preleptotene spermatocytes should stain (High; HPA: testis). Use adipose tissue as the negative tissue, where adipocytes are Not detected (HPA: adipose tissue); other cells on the testis slide should provide an internal negative background reference, without assuming a particular cell type is negative.

Positive control tissue: Testis (Preleptotene spermatocytes, HPA High)

Negative control tissue: Adipose tissue (HPA Not detected)

ICC-IF cell lines (HPA subcellular resource): HPA ICC-IF images show IGF2BP1 in CACO-2, Hep-G2, U2OS, with annotated localisation: Cytosol (supported) (HPA subcellular).

Technical controls: Include no-primary (secondary-only) and host- and clonality-matched isotype controls, plus an IGF2BP1 knockout sample or validated peptide-block control where available (standard IHC practice). On the testis slide, check for endogenous peroxidase and biotin signal with appropriate blocking and detection controls (standard chromogenic IHC practice).

⚠️Feasibility: No target-specific fixation window or fixation effect is reported in the supplied evidence; the selected A02007-1 tissue-IHC caption does not establish a fixative (selected-SKU caption: fixative unreported). The caption reports heat retrieval in citrate buffer at pH 6, but does not establish that retrieval is required for every specimen (selected-SKU caption: citrate retrieval). For IF/ICC, HPA reports mainly cytosolic localization and images in CACO-2, Hep-G2 and U2OS; the supplied evidence does not establish whether frozen sections or IF are easier than paraffin IHC (HPA: subcellular).

HPA tissue IHC evidence for IGF2BP1

Comprehensive Human Protein Atlas IHC scoring per tissue (reliability: Enhanced — Medium consistency between antibody staining and RNA expression data.). Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.

Positive expression · recommended positive controls

Tissue	Cell type	Level	Evidence	Source
Testis	Preleptotene spermatocytes	High	Protein (IHC)	HPA →
Kidney	Collecting ducts	Medium	Protein (IHC)	HPA →
Ovary	Follicle cells	Medium	Protein (IHC)	HPA →

Undetected expression · recommended negative controls

Tissue	Cell type	Level	Evidence	Source
Adipose tissue	Adipocytes	Not detected	Protein (IHC)	HPA →
Adrenal gland	Glandular cells	Not detected	Protein (IHC)	HPA →
Appendix	Glandular cells	Not detected	Protein (IHC)	HPA →
Bone marrow	Hematopoietic cells	Not detected	Protein (IHC)	HPA →
Breast	Adipocytes	Not detected	Protein (IHC)	HPA →

Section 3

Advanced IGF2BP1 IHC Tips

IGF2BP1 is mainly cytosolic, with tissue staining concentrated in selected cell populations (HPA tissue IHC; HPA subcellular).

How should I troubleshoot weak IGF2BP1 staining after antigen retrieval?

Start with heat-mediated retrieval in citrate buffer at pH 6 (datasheet A02007-1). If staining is weak, check that sections stayed submerged, the buffer reached the intended temperature, and slides cooled consistently before staining (standard IHC practice). Compare a short and a longer heating interval on serial sections while keeping antibody dilution and detection identical; excessive heating can damage morphology or increase background (standard IHC practice). Use testis as a comparison tissue and inspect preleptotene spermatocytes rather than judging the entire section uniformly (HPA: High in testis preleptotene spermatocytes). Record retrieval time alongside staining intensity and tissue preservation (standard IHC practice).

Could fixation explain weak or uneven IGF2BP1 staining?

Target-specific sensitivity of IGF2BP1 staining to fixation is unknown from the supplied evidence. For paraffin-section IHC, compare sections with documented fixation duration and similar processing before changing antibody or retrieval conditions (standard IHC practice). Prolonged fixation may reduce epitope access, whereas uneven fixation can produce regional staining differences; assess both possibilities against tissue morphology (standard IHC practice). Keep citrate retrieval at pH 6 constant during that comparison (datasheet A02007-1). Include a known staining region on each run, and avoid assigning a weak result to IGF2BP1 biology until processing variation and detection performance have been checked (standard IHC practice).

Which staining compartment should I expect, and when is nuclear staining credible?

Expect predominantly cytoplasmic staining in tissue sections, particularly in cells of testis seminiferous ducts and ovarian follicles (HPA tissue IHC profile). IGF2BP1 is mainly cytosolic, although nuclear foci and perinuclear or granular cytoplasmic locations are described (HPA subcellular; UniProt Q9NZI8 subcellular location). Score cytoplasm and nuclei separately so a nuclear-only pattern does not silently count as the expected tissue signal (standard IHC practice). Examine whether staining respects cell boundaries and persists across intact regions rather than appearing only at section edges (standard IHC practice). Treat discrete nuclear signal as provisional until it reproduces with appropriate controls and matches the sampled cell population (standard IHC practice).

Can isoforms or epitope location explain discordant staining?

The record lists 2 IGF2BP1 isoforms and a 577-residue canonical chain containing RRM and KH RNA-binding domains (UniProt Q9NZI8 isoforms, processing and domains). Without the catalog antibody's epitope map, its recognition of each isoform or modified state cannot be determined from this payload. Check the immunogen or epitope documentation before interpreting a negative section as absence of all IGF2BP1 forms (standard IHC practice). Compare staining across serial sections under identical retrieval and detection conditions, then confirm any suspected isoform difference with an independent method suited to isoform discrimination (standard IHC practice). Do not infer epitope accessibility from domain position alone (standard IHC practice).

How can I assess IGF2BP1 by multiplex IF in the same specimen?

Use a second marker that identifies the expected cell population, then evaluate IGF2BP1 within those cells; preleptotene spermatocytes or ovarian follicle cells are tissue-based reference populations (HPA tissue IHC). Choose spectrally separated fluorophores and place the weaker signal in a channel with low measured tissue autofluorescence (standard IF practice). IGF2BP1 has no transmembrane segment and is mainly cytosolic, so include a controlled permeabilisation step when testing IF access to the intracellular epitope (UniProt Q9NZI8 topology; HPA subcellular; standard IF practice). Acquire single-stain and unstained controls with identical settings to assess bleed-through and autofluorescence (standard IF practice). IF conditions require their own validation (standard IF practice).

What should I change when cytoplasmic staining spreads across the section?

First distinguish diffuse staining in many cell types from the more restricted tissue pattern: testis preleptotene spermatocytes are High, while adipocytes in adipose tissue are Not detected (HPA tissue IHC). Run a no-primary control and check endogenous peroxidase blocking, biotin-related detection background where applicable, and chromogen development time (standard chromogenic IHC practice). Titrate the primary around the caption's 1:25 condition and compare serial sections using the same retrieval and detection steps (A02007-1 tissue-IHC caption; standard IHC practice). Maintain consistent protein blocking; the selected image reports 3% BSA for 0.5 hour (A02007-1 tissue-IHC caption). Judge any improvement against retained cellular contrast (standard IHC practice).

How should I quantify IGF2BP1 across sections with different cell composition? ⚠ ANSWER MARKED FOR VERIFICATION

Define the compartment and cell population before scoring; cytoplasmic staining is the principal tissue pattern (HPA tissue IHC profile). For comparable regions, report the percentage of positive target cells and an H-score based on the proportion at each intensity level, using the same thresholds across slides (standard IHC practice). Normalise to the number of eligible cells or annotated tissue area, such as positive cells per mm², rather than total section area when cellularity differs (standard IHC practice). Exclude folds, necrosis and poorly preserved margins using prespecified rules (standard IHC practice). Report testis preleptotene spermatocytes separately from other cells when that population is available (HPA: High in testis preleptotene spermatocytes).

How do I separate genuine IGF2BP1 signal from section artefacts?

A convincing result follows the expected cytoplasmic pattern within plausible cells: HPA reports High staining in testis preleptotene spermatocytes and Medium staining in ovarian follicle cells (HPA tissue IHC). IGF2BP1 may also occupy nuclear foci, so nuclear staining needs cell-level and control-based assessment rather than automatic rejection (UniProt Q9NZI8 subcellular location; standard IHC practice). Treat staining confined to cut edges, folds or necrotic areas as suspect, particularly if adjacent intact tissue lacks the pattern (standard IHC practice). Check a no-primary section for endogenous enzyme or detection-system signal before attributing diffuse chromogen to IGF2BP1 (standard chromogenic IHC practice). Interpret negative cells against the sampled tissue and processing controls (standard IHC practice).

Boster reagents

Best IGF2BP1 / Insulin-like growth factor 2 mRNA-binding protein 1 IHC Antibodies

A02007-1 has real IHC images from human testis and lung adenocarcinoma paraffin sections (A02007-1 IHC captions); the catalog lists human and mouse reactivity (catalog: A02007-1).

Real IHC data

Anti-IGF2BP1 Antibody (C-term)

Cat # A02007-1

View product →

A02007-1 has IHC-P images from human testis and lung adenocarcinoma paraffin sections (A02007-1 IHC captions). Its listed applications include IHC-P, while its listed reactivity is human and mouse (catalog: A02007-1).

Which to pick: Choose A02007-1 for paraffin-section IHC: it is a rabbit polyclonal antibody with IHC-P listed and human tissue images at 1:25 (catalog: A02007-1; A02007-1 IHC captions). No IF/ICC application or IF image is listed for A02007-1, so this payload does not support an IF/ICC recommendation (catalog: A02007-1). A02007-1 lists mouse reactivity, but its supplied IHC images are human; its captions describe fixation as both paraformaldehyde and formaldehyde, so confirm the processing details before following them (catalog: A02007-1; A02007-1 IHC captions).

Each figure is that product's own IHC / IF validation image from its datasheet.

References

UniProt Consortium. UniProt entry Q9NZI8 (IF2B1_HUMAN, Insulin-like growth factor 2 mRNA-binding protein 1).
Human Protein Atlas. IGF2BP1 tissue IHC expression (reliability: Enhanced).
Human Protein Atlas. IGF2BP1 subcellular location (ICC-IF): Mainly localized to the cytosol..
Human Protein Atlas. IGF2BP1 antibody validation summary (2 antibodies).
MicroRNAs as potential indicators of the development and progression of uterine leiomyoma. PloS one 2022 — PMC9154092.
Differences in the expression profiles of m6A-related genes and the prognostic role in immunotherapy for lung adenocarcinoma patients. Frontiers in oncology 2026 — PMC12967950.
IGF2BP1/HMOX1 Mediates Fate Determinations of Human Spermatogonial Stem Cells and Male Infertility via an m6A-Dependent Manner. Research (Washington, D.C.) 2025 — PMC12635413.
Expression of microRNA-150 and its Target Gene IGF2BP1 in Human Osteosarcoma and their Clinical Implications. Pathology oncology research : POR 2019 — PMC6449306.
PubMed PMID:16625196 — UniProt-cited evidence.
PubMed PMID:9891060 — UniProt-cited evidence.
PubMed PMID:16356927 — UniProt-cited evidence.